When Biogen and its partner Eisai announced in March that they’d halted two simultaneous Phase 3 clinical trials on an Alzheimer’s drug based on disappointing
A small clinical trial testing the safety of administering young people’s blood plasma to treat Alzheimer’s disease has found that the approach may slightly improve